VALSE: Integration of Neuromodulation and Exoskeleton Systems for Mobility in Individuals With Chronic Spinal Cord Injury (VALSE)
2026년 8월 3일 업데이트: Jocelyne Bloch, Ecole Polytechnique Fédérale de Lausanne
The purpose of this clinical study is to evaluate the preliminary safety and feasibility of using the VALSE system, which combines spinal cord stimulation with the TWIICE robotic exoskeleton, to support motor recovery and reduce reliance on laboratory-based equipment during rehabilitation in participants with traumatic spinal cord injury.
The TWIICE exoskeleton is integrated through the NR system, a platform developed by EPFL.
The goal is to assess the clinical safety and practical application of this combined neuroprosthetic approach in a small number of participants, in order to guide future refinements of the device and protocol, support the development of scalable interventions integrating spinal stimulation with robotic assistance, and inform strategies for delivering rehabilitation in more accessible, real-world environments.
연구 개요
상태
상태
아직 모집하지 않음
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Spinal cord injury (SCI) disrupts communication between the brain and spinal cord below the lesion, often resulting in severe and permanent motor impairments. Despite advances in rehabilitation, recovery of walking remains limited and restoring mobility is consistently identified as a top priority by individuals living with SCI.
Epidural electrical stimulation (EES) of the spinal cord has emerged as a promising approach to restore movement after paralysis. By activating spinal motor circuits below the lesion, EES can enable standing, stepping, and walking in individuals with chronic SCI. ONWARD Medical has developed the ARC-IM spinal stimulation platform, which is currently being evaluated in several clinical studies, including BoxSwitch (NCT05942339), Think2Go (NCT06243952), and STIMO-BSI (NCT04632290).
In the BoxSwitch trial, optimized spatiotemporal EES protocols enabled participants with chronic SCI to perform standing, stepping, and walking movements. Building on these findings, the Think2Go and STIMO-BSI studies integrated the WIMAGINE implantable electrocorticography (ECoG) system developed by Clinatec (CEA, Grenoble, France) with spinal stimulation, creating a brain-spine interface capable of decoding motor intentions and translating them into spinal stimulation. These studies demonstrated that implantable brain-spine interfaces can restore voluntary control of lower-limb movements and support functional walking after severe paralysis.
Although these technologies have shown encouraging results, their use remains largely restricted to specialized rehabilitation settings. In parallel, robotic exoskeletons have been developed to support overground walking in individuals with SCI. The TWIICE exoskeleton is a lightweight and modular system specifically designed for use beyond rehabilitation centers and may complement spinal stimulation by providing functional support during walking.
In this study, the investigators will evaluate the preliminary safety and feasibility of the VALSE system, which combines the ARC-IM spinal cord stimulation platform with the TWIICE robotic exoskeleton in individuals with chronic traumatic SCI. Participants will be recruited from ongoing clinical studies at Lausanne University Hospital (CHUV), including BoxSwitch (NCT05942339), Think2Go (NCT06243952), and STIMO-BSI (NCT04632290), after completion of the relevant study phases.
As an early feasibility investigation, the study aims to generate preliminary safety and usability data on the combined use of spinal neuromodulation and robotic assistance during mobility tasks. The results will support the development of future neuroprosthetic solutions designed to improve walking ability, independence, and quality of life for people living with SCI.
연구 유형
연구 유형
중재적
등록 (추정된)
등록
12
단계
단계
- 해당 없음
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 연락처
연구 연락처
- 이름: Henri Lorach, PhD
- 전화번호: +41 77 495 50 48
- 이메일: henri.lorach@epfl.ch
연구 연락처 백업
- 이름: Jocelyne Bloch, Prof.
- 전화번호: +41 79 556 29 51
- 이메일: jocelyne.bloch@chuv.ch
연구 장소
-
-
Canton of Vaud
-
Lausanne, Canton of Vaud, 스위스, 1005
- Centre Hospitalier Universitaire Vaudois (CHUV)
-
연락하다:
- Jocelyne Bloch
- 전화번호: 0795568979
- 이메일: Jocelyne.bloch@chuv.ch
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
아니
설명
Inclusion Criteria:
- Currently enrolled participants who have completed the relevant phase of their parent study at CHUV: BoxSwitch (NCT05942339, after the optimisation phase), Think2Go (NCT06243952, after the rehabilitation phase, or STIMO-BSI (NCT04632290, after the calibration and training phase of the optional extension with system upgrade),
- Must have a functional neuromodulation system,
- Must be at least 18 years old,
- Must be suffering from non-progressive traumatic spinal cord injury, sustained at least 12 months before signing the consent form,
- Must weigh less than 100 kg,
- Must have a standing height between 160 and 190 cm,
- Must be able to grasp and lift bilateral crutches in a seated position,
- Must have stable medical, physical and psychological condition as considered by the investigator,
- Must be able to understand and interact with the study team in French or English,
- Must agree to comply in good faith with all conditions of the study and to attend all scheduled appointments,
- Must provide Informed Consent as documented by signature prior to any study-related procedures.
Exclusion Criteria:
- Must not be diagnosed with severe osteoporosis/penia:
Dual Energy X-ray Absorptiometry (DEXA) results indicating a t-score below -3.5 at either the femoral neck or the total proximal femur.
Dual Energy X-ray Absorptiometry (DEXA) results indicating a bone mineral density (BMD) < 0.60 gm/cm2 at any knee region (distal femur, proximal tibia)
- Must not have deep vein thrombosis in lower extremities within the past 6 months.
- Must not have experienced lower extremity fractures within the last two years.
- Must not have current pressure ulcer of the arms, trunk, pelvic area, or lower extremities
- Must not present with a flexion contracture >15° at the hip or knee
- Must not have severe concurrent medical conditions that contraindicate moderate to intense exercise (e.g., uncontrolled hypertension, coronary artery disease, congestive heart failure).
- Must not have heterotopic ossification that impairs joint mobility
- Must not be implanted with a life-supporting medical device (devices implanted in the parent study are not considered life-supporting),
- Must not be pregnant,
- Must not be the investigator himself, his/her family members, employees, or other dependent persons.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
1
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: All participant
All participants receive the same intervention. Each participant will complete 3 predefined study periods within 1 year of enrolment. Each study period lasts 3 weeks, and study periods are separated by a minimum interval of 1 month. |
Participants will use the VALSE system, which combines the TWIICE Rise 1.0 robotic exoskeleton with epidural electrical stimulation (EES) delivered through previously implanted neuromodulation systems.
The system is intended to support upright mobility and overground walking in individuals with chronic spinal cord injury (SCI) who are currently enrolled in, or have completed key phases of, neuromodulation clinical trials at CHUV, including Think2Go (NCT06243952), STIMO-BSI (NCT04632290), and BoxSwitch (NCT05942339).
The TWIICE exoskeleton provides robotic gait assistance, while EES facilitates activation of spinal motor circuits below the level of injury.
Exoskeleton movements are initiated and controlled through participant-generated inputs, including finger-click commands and, where applicable, brain-derived control signals from previously implanted brain-spine interface systems.
The VALSE system is used in supervised clinical and controlled real-world.
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Preliminary safety
기간: From enrollment until the end of study timepoint, up to 1 year after enrollment.
|
Occurrence of Serious Adverse Events (SAE) and Adverse Events (AE) that are deemed related or possibly related to the procedure or to the TWIICE exoskeleton in combination with the neuromodulation therapies (VALSE system)
|
From enrollment until the end of study timepoint, up to 1 year after enrollment.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Assessment of the experimental session conditions
기간: At each in-clinic training session during the three study periods, up to 1 year after enrollment.
|
Location and type of ground walked on.
|
At each in-clinic training session during the three study periods, up to 1 year after enrollment.
|
|
Number of steps
기간: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
Total number of steps recorded by the exoskeleton during each experimental (EX) session.
|
At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
|
Step frequency
기간: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
Average step frequency (cadence) recorded by the exoskeleton during each experimental (EX) session.
|
At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
|
Mid-stride pauses
기간: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
Number of mid-stride pauses recorded by the exoskeleton during each experimental (EX) session.
|
At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
|
Distance walked
기간: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
Total distance walked recorded by the exoskeleton during each experimental (EX) session.
|
At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
|
Walking time
기간: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
Total walking time recorded by the exoskeleton during each experimental (EX) session.
|
At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
|
Standing time
기간: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
Total standing time recorded by the exoskeleton during each experimental (EX) session.
|
At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
|
Kinematic gait parameters
기간: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
Kinematic gait parameters recorded during overground walking and functional locomotor tasks (change of walking speed, stepping over and turn around obstacles, climb stairs, walk with cognitive load (e.g., counting backward by threes)) using the VALSE system.
|
At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
|
Electromyographic (EMG) activity
기간: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
Muscle activation patterns recorded by surface electromyography during overground walking and functional locomotor tasks while using the VALSE system.
|
At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
|
Brain-computer interface (BCI) performance
기간: At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
Brain-computer interface performance metrics recorded during overground walking and functional locomotor tasks while using the VALSE system.
|
At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
|
Donning and Doffing Time
기간: At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.
|
Assessment of the time it takes to put on and take off the system.
Donning time is recorded from the start of preparation until the participant is fully ready for ambulation.
Doffing time is recorded from the start of removal until the participant is fully disengaged from the system.
|
At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.
|
|
Level of Assistance (LOA)
기간: At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.
|
Assessment to evaluates the amount of physical support required by the participant during walking and mobility activities with the device.
|
At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.
|
|
System Usability Scale (SUS)
기간: At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.
|
A validated 10-item questionnaire measuring usability across multiple domains.
Scores range from 0-100, with higher values indicating greater usability.
Will be filled in by participants and physiotherapists.
|
At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.
|
|
ASA Task Load Index (NASA-TLX)
기간: At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.
|
A 6-dimension tool assessing perceived workload (mental demand, physical demand, temporal demand, performance, effort, frustration).
Will be filled in by participants and physiotherapists.
|
At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
수사관
수사관
- 수석 연구원: Jocelyne Bloch, Prof., Centre Hospitalier Universitaire Vaudois (CHUV)
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
일반 간행물
- Rowald A, Komi S, Demesmaeker R, Baaklini E, Hernandez-Charpak SD, Paoles E, Montanaro H, Cassara A, Becce F, Lloyd B, Newton T, Ravier J, Kinany N, D'Ercole M, Paley A, Hankov N, Varescon C, McCracken L, Vat M, Caban M, Watrin A, Jacquet C, Bole-Feysot L, Harte C, Lorach H, Galvez A, Tschopp M, Herrmann N, Wacker M, Geernaert L, Fodor I, Radevich V, Van Den Keybus K, Eberle G, Pralong E, Roulet M, Ledoux JB, Fornari E, Mandija S, Mattera L, Martuzzi R, Nazarian B, Benkler S, Callegari S, Greiner N, Fuhrer B, Froeling M, Buse N, Denison T, Buschman R, Wende C, Ganty D, Bakker J, Delattre V, Lambert H, Minassian K, van den Berg CAT, Kavounoudias A, Micera S, Van De Ville D, Barraud Q, Kurt E, Kuster N, Neufeld E, Capogrosso M, Asboth L, Wagner FB, Bloch J, Courtine G. Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis. Nat Med. 2022 Feb;28(2):260-271. doi: 10.1038/s41591-021-01663-5. Epub 2022 Feb 7.
- Gorgey AS, Gill S, Holman ME, Davis JC, Atri R, Bai O, Goetz L, Lester DL, Trainer R, Lavis TD. The feasibility of using exoskeletal-assisted walking with epidural stimulation: a case report study. Ann Clin Transl Neurol. 2020 Feb;7(2):259-265. doi: 10.1002/acn3.50983. Epub 2020 Feb 5.
- Hong E, Gorman PH, Forrest GF, Asselin PK, Knezevic S, Scott W, Wojciehowski SB, Kornfeld S, Spungen AM. Mobility Skills With Exoskeletal-Assisted Walking in Persons With SCI: Results From a Three Center Randomized Clinical Trial. Front Robot AI. 2020 Aug 4;7:93. doi: 10.3389/frobt.2020.00093. eCollection 2020.
- Vouga T, Fasola J, Baud R, Manzoori AR, Pache J, Bouri M. TWIICE One powered exoskeleton: effect of design improvements on usability in daily life as measured by the performance in the CYBATHLON race. J Neuroeng Rehabil. 2022 Jun 27;19(1):63. doi: 10.1186/s12984-022-01028-0.
- Zhang T, Jia Y, Wang N, Chai X, He Q, Cao T, Mu Q, Lan Q, Zhao J, Yang Y. Recent advances in potential mechanisms of epidural spinal cord stimulation for movement disorders. Exp Neurol. 2025 Oct;392:115330. doi: 10.1016/j.expneurol.2025.115330. Epub 2025 Jun 4.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (추정된)
연구 시작
2026년 9월 15일
기본 완료 (추정된)
기본 완료
2028년 5월 1일
연구 완료 (추정된)
연구 완료
2028년 9월 1일
연구 등록 날짜
최초 제출
최초 제출
2026년 6월 25일
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
2026년 8월 3일
처음 게시됨 (실제)
처음 게시됨
2026년 8월 4일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
2026년 8월 4일
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
2026년 8월 3일
마지막으로 확인됨
마지막으로 확인됨
2026년 8월 1일
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
기타 연구 ID 번호
- VALSE
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
아니요
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
아니
미국 FDA 규제 기기 제품 연구
아니
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .